Leber Congenital Amaurosis Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About Leber Congenital Amaurosis
Leber Congenital Amaurosis (LCA) is a rare genetic eye disorder causing severe vision loss from infancy. Facing such a diagnosis can be overwhelming, especially when considering the costs of ongoing care and specialized treatments. TheDrugClub is dedicated to easing this burden, helping members afford essential medications and therapies, ensuring access to the support they need.
Leber Congenital Amaurosis (LCA) is a group of inherited retinal diseases that are among the most common causes of congenital blindness. Typically, infants with LCA are born with severely impaired vision or are completely blind. This condition arises from mutations in various genes responsible for the normal function and development of the retina, the light-sensitive tissue at the back of the eye.
Children with LCA often exhibit characteristic signs such as nystagmus (involuntary, rapid eye movements), photophobia (extreme sensitivity to light), and a sluggish or absent pupillary light reflex. They may also display the oculodigital reflex, where they frequently press or rub their eyes. Diagnosis usually involves a combination of clinical examination, electroretinography (ERG) to measure retinal electrical activity, and genetic testing to identify the specific gene mutation responsible.
For many years, there were no specific treatments for LCA, and care focused on supportive measures like low vision aids, mobility training, and occupational therapy. However, medical science has made significant strides. A notable breakthrough is gene therapy, specifically for individuals with LCA caused by mutations in the *RPE65* gene. This innovative treatment involves injecting a modified virus containing a functional copy of the *RPE65* gene directly into the retina, which can improve vision for some patients. While this
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.